O’Neil Health Care Weekly

XLV declined 2.1% last week, reversing from 200-DMA resistance ($147.62). This and the falling 21-DMA ($146.15) remain near-term
resistance. Support is at its recent low of $140.26. Its RS line has fallen to another new low, still warranting an underweight sector
positioning.

Market View

The U.S. market remains in a Confirmed Uptrend. The S&P 500 and Nasdaq gained 1.0% and 3.3%, respectively, this week, and are at all-time highs. Support is at their rising 10-DMA (6,036; 19,368) and then their 21-DMA (5,985, 19,200). The distribution day count is at three and one, respectively, after two expired on the S&P 500 during the week.

IPO Rewind

Attached is our monthly IPO Rewind report. This report identifies a select group of IPOs or spin-offs that have priced in the last two years, giving them time to digest any initial volatility. Our selected ideas display positive fundamental trends with strong top- and bottom-line consensus estimates, and IPO Rewind provides an efficient way to review these ideas that we believe warrant attention.

O’Neil Health Care Weekly

XLV gained 2.3%, rallying for the second straight week from oversold levels, but now set to test key resistance at its 200-DMA
($147.61) followed by its 50-DMA ($149.55). Near-term support is at its 21-DMA ($146.32). Its RS line remains near lows, still
warranting an underweight sector positioning.

Market View

The U.S. market remains in a Confirmed Uptrend. The S&P 500 and Nasdaq gained ~1% for the week after holding above support at their rising 10-and-21 DMA (5,932, 18,922). The distribution day count remains at five and one, respectively, however two days expire on the S&P 500 during the middle of next week.

O’Neil Health Care Weekly

XLV gained 1.6% last week, after falling over 5% the week prior. The sector is attempting to hold support near ~$142, despite still
facing multiple levels of moving average resistance including the 21-DMA ($146.21; +1.4%) followed by the 200-DMA ($147.55;
+2.3%). Its RS line is now at the lowest levels since 2008, still warranting an underweight sector positioning. We continue to expect
choppy trendless action in the sector over the next few weeks.

Market View

The U.S. market remains in a Confirmed Uptrend. This week, the S&P 500 and the Nasdaq closed about 1.7% higher. Indices have immediate support at their 21-DMA (5,895/18,825), ~1% below current levels. Next support is at their rising 50-DMA (5,810/18,428), ~2–3% below current levels. The distribution day count remains at six and one, respectively, with one set to expire on the S&P 500 in the coming week.

O’Neil Health Care Weekly

XLV declined 5.55% last week, marking its worst weekly decline since 2020. The index breached all key moving averages including
its 200-DMA ($147.57). Next support is at $140.68, followed by $138.21. Its RS line continues to make new lows, warranting an
underweight sector positioning. Despite the sector again being oversold, we expect choppy trendless action over the next few weeks
given last week’s break lower and little to no ideas setup technically to buy.

Market View

The U.S. market remains in a Confirmed Uptrend. Indices pulled back after last week’s strong election gains. The S&P 500 declined ~2% and is testing 21-DMA (5,871) support, while the Nasdaq fell ~3% and closed below its 21-DMA (18,748). The next level of support is at the rising 50-DMA (5,772, 18,264), which is ~2% lower. The distribution day count stands at six and two, respectively. with one day expiring on each index after the close on Monday.

O’Neil Health Care Weekly

XLV gained 165 bps last week after rallying from 200-DMA ($147.43) support. Immediate resistance is at its 100-DMA ($150.97),
followed by its 50-DMA ($152.58). Though an oversold absolute rally is likely to continue, we still recommend an underweight sector
positioning given the Relative Strength (RS) line remains at its lowest levels since 2011.